ESR1 and breast carcinoma: In the PALOMA-2 study conducted by Finn et al., there is strong evidence of significantly longer progression-free survival amongst post-menopausal women with ER-positive, HER2-negative advanced breast cancer in those who received combined treatment with endocrine therapy and CDK 4/6 inhibitor compared to those who only received endocrine therapy [8].